These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27700100)

  • 1. Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis.
    Darrah E; Kim A; Zhang X; Boronina T; Cole RN; Fava A; Giles JT; Bingham III CO; Chalmers MJ; Griffin PR; Sadegh-Nasseri S; Rosen A
    J Proteome Res; 2017 Jan; 16(1):355-365. PubMed ID: 27700100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.
    Darrah E; Rosen A; Giles JT; Andrade F
    Ann Rheum Dis; 2012 Jan; 71(1):92-8. PubMed ID: 21859690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
    Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
    Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
    Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
    J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
    Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
    Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
    Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
    Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
    Blachère NE; Parveen S; Frank MO; Dill BD; Molina H; Orange DE
    Arthritis Rheumatol; 2017 May; 69(5):986-995. PubMed ID: 28029744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
    Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
    Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidylarginine deiminase 4 and citrullination in health and disease.
    Anzilotti C; Pratesi F; Tommasi C; Migliorini P
    Autoimmun Rev; 2010 Jan; 9(3):158-60. PubMed ID: 19540364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of Distinct Patterns of Rheumatoid Arthritis Autoantigens by Peptidylarginine Deiminase Types 2 and 4 During Perforin-Induced Cell Damage.
    Romero V; Darrah E; Andrade F
    Arthritis Rheumatol; 2020 Jun; 72(6):912-918. PubMed ID: 31876120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
    Zhao J; Zhao Y; He J; Jia R; Li Z
    J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
    Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
    Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
    Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
    Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to PAD4 and BRAF in rheumatoid arthritis.
    Auger I; Charpin C; Balandraud N; Martin M; Roudier J
    Autoimmun Rev; 2012 Sep; 11(11):801-3. PubMed ID: 22349616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid.
    Spengler J; Lugonja B; Ytterberg AJ; Zubarev RA; Creese AJ; Pearson MJ; Grant MM; Milward M; Lundberg K; Buckley CD; Filer A; Raza K; Cooper PR; Chapple IL; Scheel-Toellner D
    Arthritis Rheumatol; 2015 Dec; 67(12):3135-45. PubMed ID: 26245941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis.
    Takizawa Y; Sawada T; Suzuki A; Yamada R; Inoue T; Yamamoto K
    Scand J Rheumatol; 2005; 34(3):212-5. PubMed ID: 16134727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
    Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
    Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
    Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Interplay between the Dimer Interface and the Substrate-Binding Site of Human Peptidylarginine Deiminase 4.
    Lee CY; Lin CC; Liu YL; Liu GY; Liu JH; Hung HC
    Sci Rep; 2017 Feb; 7():42662. PubMed ID: 28209966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.